Emmecell
CompanyUnited States
Emmecell develops one asset, in phase 2 (EO2002 in corneal edema). Mostly cell therapy; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 2
- Signals
Pipeline
1Magnetic human corneal endothelial cells replace lost endothelial cells to restore corneal function and reduce edema.
Phase 2, Cell therapy, corneal edema, corneal endothelial cell loss
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Signals2